Theriva Biologics Raised to Buy From Hold by Maxim Group

robot
Abstract generation in progress

Maxim Group has upgraded Theriva Biologics (NYSE:TBIO) from a Hold rating to a Buy rating. The firm also set a new price target of $9.00 for the company’s stock. This upgrade suggests a positive outlook on Theriva Biologics’ future performance.

This page may contain third-party content, which is provided for information purposes only (not representations/warranties) and should not be considered as an endorsement of its views by Gate, nor as financial or professional advice. See Disclaimer for details.
  • Reward
  • Comment
  • Repost
  • Share
Comment
Add a comment
Add a comment
No comments